期刊文献+

冠心宁联合利伐沙班治疗老年下肢静脉血栓临床探究

Clinical Study of Guanxinning Combined with Rivaroxaban in the Treatment of Venous Thrombosis of Lower Extremities in the Elderly
原文传递
导出
摘要 目的探究冠心宁联合利伐沙班治疗老年下肢静脉血栓临床效果。方法此次采取随机数字表分组法,将该院于2017年1—12月收治的80例老年下肢静脉血栓患者分成两个不同的组别,每组平均为40例;其中,对照组患者给予基础治疗,观察组患者加用冠心宁、利伐沙班进行治疗,对比两组疗效。结果经治疗,观察组的治疗总有效率为95.00%,显著高于对照组的82.50%,两组数据差异有统计学意义(P<0.05)。结论冠心宁联合利伐沙班治疗老年下肢静脉血栓,疗效显著,值得在临床实践中采纳应用。 Objective To investigate the clinical effect of Guanxinning combined with rivasha in the treatment of lower extremity venous thrombosis in the elderly.Methods 80 elderly patients with venous thrombosis of lower extremities treated in our hospital from January to December 2017 were divided into two different groups with an average of 40 cases in each group.The patients in the control group were treated with basic therapy,and the patients in the observation group were treated with Guanxinning and rivasha,and the curative effects were compared between the two groups.Results After treatment,the total effective rate of the observation group was 95.00%,which was significantly higher than that of the control group(82.50%).The difference between the two groups was significant(P<0.05).Conclusion Guanxinning combined with rifampican is effective in the treatment of venous thrombosis of lower extremities in the elderly,and it is worthy to be adopted in clinical practice.
作者 杨孝永 YANG Xiaoyong(Yitang Central Hospital,Linyi Shandong,276000,China)
机构地区 义堂中心卫生院
出处 《双足与保健》 2019年第11期9-10,共2页 Biped and Health
关键词 冠心宁 利伐沙班 治疗 老年下肢静脉血栓 Guanxinning Rivaroxaban Treatment Venous thrombosis of lower limbs in the elderly
  • 相关文献

参考文献6

二级参考文献33

  • 1SAMAMA M M, MARTINOLI J L,LEFLEM L, et al.Assessment of laboratory assays to measure rivaroxaban-anoral, direct factor Xa inhibitor [J].Thromb Haemost, 2010,103(4): 815-825.
  • 2CAPPATO R, EZEKOWITZ M D, KLEIN A L, et al.Rivaroxaban vs. vitamin K antagonists for cardioversion inatrial fibrillation [J].Eur Heart J, 2014, 35(47): 3346-3355.
  • 3KOROSTELEV M, BIHAN K, FERREOL L, et al.Simultaneous determination of rivaroxaban and dabigatranlevels in human plasma by high-performance liquidchromatography-tandem mass spectrometry [J].J PharmBiomed Anal, 2014, 100: 230-235. Doi: 10.1016/j.jpba.2014.08.011.
  • 4WEINZ C, SCHWARZ T, KUBITZA D, et al. Metabolismand excretion of rivaroxaban, an oral, direct factor Xa inhibitor,in rats, dogs, and humans [J].Drug Metab Dispos, 2009, 37(5):1056-1064.
  • 5DOUXFILS J,TAMIGNIAU A, CHATELAIN B, et al.Comparison of calibrated chromogenic anti-Xa assay and PTtests with LC-MS/MS for the therapeutic monitoring ofpatients treated with rivaroxaban [J].Thromb Haemost, 2013,110(4): 723-731.
  • 6KUBITZA D, BECKA M, MUECK W, et al. Safety,tolerability, pharmacodynamics, and pharmacokinetics ofrivaroxaban-an oral, direct factor Xa inhibitor-are not affectedby aspirin [J].J Clin PharmacoL, 2006, 46(9): 981-990.
  • 7KLOTZ U. Pharmacokinetics and drug metabolism in theelderly [J].Drug Metab Rev, 2009, 41(2): 67-76.
  • 8VIVENCIO B, CARLOS E.Rivaroxaban: a once-daily antico- agulant for the prevention of thromboembolic complications [J].Exp Rev Card Ther,2013,11(2):129-141.
  • 9LALIBERTE F, CLOUTIER M, NELSON W, et al.Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients [ J ]. Curr Med Res Opin,2014,30(7) :1317-1325.
  • 10WEITZ J I, GROSS P L.New oral anticoagulants:which one should my patient use? [ J] .Hematology Am Soe Hematol Educ Program, 2012,2012 : 536-540.

共引文献49

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部